<DOC>
	<DOCNO>NCT00619905</DOCNO>
	<brief_summary>This study assess long-term safety tolerability ACZ885 patient rheumatoid arthritis , well long-term efficacy , long-term preservation and/or improvement joint structure bone mineral density , long term maintenance health-related quality life .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics ACZ885 Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Male female patient age 18.5 65/75 year ( depend dose group ) . Diagnosis rheumatoid arthritis ( ACR 1987 revise classification criterion RA ) disease duration least 6 month prior randomization . Active disease screen baseline evaluation ( evaluator ) ) 6 tender 6 swollen joint 28 examine ( include effuse joint ) either ) Westergren erythrocyte sedimentation ( ESR ) ≥ 28 mm/hour , b ) CRP ≥ 6 mg/L . Patients fail least 1 DMARD past , deem `` refractory therapy '' Patients current treatment regimen ≥ 15 mg methotrexate/week current dose stable approximately 3 month . Patients required otherwise stable RA therapeutic regimen , consist either stable dose NSAIDs and/or stable dose oral corticosteroid ( prednisone equivalent &lt; 10 mg daily ) least 4 week prior randomization . Previous treatment antiTNFα antibody therapy ( biological therapy ) within appropriate timeframe ( consider half life compound ) Patients receive intraarticular systemic corticosteroid injection require treatment acute RA flare ( part regular therapeutic regimen ) within four week prior randomization OR require narcotic analgesic accept investigator analgesia ( e.g. , codeine , tramadol , dextropropoxyphene ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anti-interleukin-1 beta</keyword>
	<keyword>ACZ885</keyword>
</DOC>